FIBROBLAST GROWTH FACTOR TYPE 1 AND 2 IN THE SERUM AT A PRIMARY MALIGNANT BONE TUMOR

Issue: 
8
Year: 
2016

E.A. Ten
Post-graduant Student, Moscow State University of Medicine and Dentistry named after A.I. Evdokimov
I.V. Babkina
Dr.Sc. (Med.), Leading Research Scientist, N.N. Blokhin Russian Cancer Research Center (Moscow)
E-mail: biochimia@yandex.ru
I.N. Kuznetsov
Ph.D. (Biol.), Moscow State University of Medicine and Dentistry named after A.I. Evdokimov (Moscow)
A.V. Bondarev
Oncologist, Moscow Oncology Hospital № 62 (Moscow)
M.Yu. Schupak
Oncologist, Moscow Oncology Hospital № 62 (Moscow)
Yu.N. Soloviev
Dr.Sc. (Med.), Professor, Academician RAS, N.N. Blokhin Russian Cancer Research Center (Moscow)
M.D. Aliev
Dr.Sc. (Med.), Professor, Academician RAS, N.N. Blokhin Russian Cancer Research Center (Moscow)

Results of comparative evaluation of type 1 and 2 fibroblast growth factors (FGF-1, FGF-2) content in blood serum of 26 practically healthy persons (control group) and 105 untreated primary bone tumor patients are presented. No independent value of serum FGF-1 and FGF-2 for pre-surgical diagnostics of bone neoplasms was revealed. FGF-1 was significantly more frequently found in bone sarcomas patients than in healthy persons sera (65.7% and 26.9% respectively; р < 0.0001). Serum FGF-1 may be regarded as an unfavorable prognostic marker of typical osteosarcoma: 5-years overall survival of such patients with detectable serum FGF-1 was 1.7 times lower than that of patients with negative serum FGF-1 (р = 0.019). It was also demonstrated that high serum levels of both FGF-1, and FGF-2 in Ewing sarcoma patients were associated with low overall survival. No associations between FGF-1 and FGF-2 serum levels and overall survival of chondrosarcoma patients were revealed.

Keywords: 
Key words: bone sarcomas
FGF-1
FGF-2
blood serum
prognosis.